PDCD1 and head and neck squamous cell carcinoma: Here, we conducted a real-world study to investigate the efficacy and feasibility of cetuximab with PD-1 inhibitors salvage therapy in patients with R/M HNSCC that relapsed from anti-PD-1 immunotherapy.